<i>ERBB2</i> mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

<i>ERBB2</i> mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the res...

Full description

Bibliographic Details
Main Authors: Gaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, Tomás Pascual, Núria Chic, Tamara Saurí, Ronald Kates, Oleg Gluz, Débora Martínez, Laia Paré, Vassilena Tsvetkova, David Pesantez, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Patricia Galván, Laura Barberá, Miriam Cuatrecasas, Mathias Christgen, Hans Kreipe, Inés Monge-Escartín, Patricia Villagrasa, Dolors Soy, Tommaso Giarratano, Maria Vittoria Dieci, Pierfranco Conte, Nadia Harbeck, Valentina Guarneri, Aleix Prat
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
<i>ERBB2</i> mRNA
HER2-positive breast cancer
T-DM1
antibody-drug conjugates
Online Access:https://www.mdpi.com/2072-6694/12/7/1902

Internet

https://www.mdpi.com/2072-6694/12/7/1902

Similar Items